CAR-ITNK cells for relapsed acute myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new immune cell therapy for people with acute myeloid leukemia (AML) that has come back or not gone away after treatment. The therapy uses your own cells, modified to target cancer cells, and may help when other treatments haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have acute myeloid leukemia (AML) that has returned or not responded to treatment.
- Your leukemia cells must have specific markers called CLL-1 and CD70.
- You must have a life expectancy of more than 3 months and be able to manage daily activities (performance status 0-3).
- Your heart, liver, kidneys, and lungs must be working well enough.
- You cannot be pregnant or breastfeeding, and you must agree to use contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a therapy made from your own immune cells, engineered to target a marker called CLL-1 on leukemia cells, for people whose AML has come back or hasn't responded to standard treatments.
This trial tests a new type of cell therapy called CAR-T, which uses specially engineered immune cells to target acute myeloid leukemia (AML) that hasn't responded to standard treatment. The goal is to see if this therapy can help patients whose cancer has come back or stopped responding to chemotherapy.
This trial tests a new treatment that uses your own immune cells, modified in the lab to find and attack leukemia cells. It's for people with AML that has come back or hasn't responded to standard treatment, and it may be followed by a stem cell transplant to help prevent the cancer from returning.
This trial tests a new type of CAR-T cell therapy that targets two proteins on leukemia cells (called CLL1 and CD33). The goal is to help people with acute myeloid leukemia that has relapsed or not responded to standard treatments.
This trial tests a new type of immune cell therapy (CAR-T) designed to find and kill leukemia cells that carry two specific markers (CLL-1 and CD33). It is for adults with acute myeloid leukemia that has come back or is not responding to standard treatments.
This trial tests a new type of cell therapy for people with a fast-growing blood cancer (AML or BPDCN) that has not improved with standard treatments. The therapy uses specially modified immune cells (called CAR T cells) to target and kill cancer cells. It may be an option for those who have run out of other treatment choices.
Hear when a new R/R AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.